Martin Samuel Bates 4
4 · Celldex Therapeutics, Inc. · Filed Jun 18, 2024
Insider Transaction Report
Form 4
Martin Samuel Bates
SVP AND CFO
Transactions
- Exercise/Conversion
Common Stock
2024-06-14$10.38/sh+16,968$176,128→ 45,297 total - Exercise/Conversion
Common Stock
2024-06-14$9.02/sh+3,201$28,862→ 28,329 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-06-14−16,968→ 63,632 totalExercise: $10.38Exp: 2030-06-18→ Common Stock (16,968 underlying) - Sale
Common Stock
2024-06-14$35.42/sh−17,172$608,315→ 28,125 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2024-06-14−3,201→ 0 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (3,201 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.89 to $35.76 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F2]As of June 13, 2022, the option is fully vested.
- [F3]As of June 18, 2024, the option is fully vested.